PLCG2 has prognostic significance in bladder neuroendocrine carcinoma
March 15, 2023
Bladder small-cell carcinoma can be divided into different subtypes depending on the expression of neuroendocrine (NE) markers such as POU2F3, NEUROD1 and ASCL1. Single-cell RNA sequencing previously found a distinct subpopulation with high expression of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2) with pro-metastatic features and poor prognosis. The aim of a newer study was to evaluate the expression of PLCG2 in bladder NE tumors and correlate it with prognostic utility.